Kuemmel S, Graeser M, Schmid P, Reinisch M, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol 2025;26:629-640.
PMID: 40318646